Building upon these discoveries, we developed an oncolytic adenovirus encoding ApoA1 and assessed its efficacy in suppressing TNBC growth and metastasis across diverse mouse models, including orthotopic breast cancer, spontaneous breast cancer, and human xenograft transplants. This evidence concerns the gene APOA1 and breast cancer.